DOCSLIB.ORG

FDA Updates Highlighting the Latest Cancer Treatments

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
FDA Updates Highlighting the Latest Cancer Treatments FDA Updates Highlighting the Latest Cancer Treatments Orphan Drug Designation of NUV-422 for (mCRC) or squamous cell carcinoma of the head and neck (SCCHN). Malignant Gliomas This approval provides for a biweekly dosage regimen option in The FDA has granted Orphan Drug Designation to NUV-422, a cyclin- addition to the previously approved weekly dosage regimen for the dependent kinase (CDK) 2/4/6 inhibitor, for the treatment of patients approved indications when cetuximab is used as a single agent or in with malignant gliomas. combination with chemotherapy. Patient enrollment and dosing is ongoing in the Phase I/II study The approval was based on population pharmacokinetic (PK) of NUV-422 in adult patients with recurrent or refractory high-grade modeling analyses that compared the predicted exposures of cetux- gliomas, including glioblastoma multiforme. The Phase I dose-esca- imab 500 mg Q2W to observed cetuximab exposures in patients who lation part of the study is designed to evaluate safety and tolerability, received cetuximab 250 mg weekly. The application was also supported as well as determine a recommended Phase II dose based on the toler- by pooled analyses of overall response rates, progression-free survival, ability profile and pharmacokinetic properties of NUV-422. The Phase and overall survival (OS) from published literature in patients with II dose expansion part of the study is expected to initially focus on CRC and SCCHN, and OS analyses using real-world data in patients patients with high-grade gliomas, and it is designed to evaluate overall with mCRC who received either the weekly cetuximab or Q2W regi- response rate, duration of response, and survival. Data from the Phase mens. In these exploratory analyses, the observed efficacy results were I portion of this study is expected in 2022. consistent across dosage regimens and supported the results of the NUV-422 is a selective small molecule resulting from a cyclin-depen- population PK modeling analyses. dent kinase (CDK) inhibitor program. CDK4/6 inhibitors are known The most common adverse reactions (incidence ≥25%) to cetux- clinical entities with proven efficacy, but cancer cells can evade these imab are cutaneous adverse reactions (including rash, pruritus, and treatments by increasing signaling through CDK2. Inhibition of CDK2 nail changes), headache, diarrhea, and infection. in addition to CDK4/6 cuts off the tumor’s natural escape route. NUV- 422 is a potent inhibitor of CDK 2, 4, and 6. Preclinical studies have Approval of Sacituzumab Govitecan for shown that NUV-422 has favorable blood-brain barrier penetration. Triple-Negative Breast Cancer The FDA Office of Orphan Drug Development grants Orphan The FDA granted regular approval to sacituzumab govitecan for pa- Drug Designation to support drug candidates in development for un- tients with unresectable locally advanced or metastatic triple-negative derserved patient populations or rare disorders that affect fewer than breast cancer (mTNBC) who have received two or more prior systemic 200,000 people in the U.S. The designation qualifies a candidate for therapies, at least one of them for metastatic disease. various development incentives, including tax credits for eligible clini- In April 2020, sacituzumab govitecan received accelerated approval cal trials, waiver of application fees, and market exclusivity for 7 years for patients with mTNBC who have received at least two prior thera- upon FDA approval. pies for metastatic disease. The following trial was the confirmatory trial for the accelerated approval. Approval of Isatuximab-Irfc for Multiple Efficacy and safety were evaluated in a multicenter, open-label, Myeloma randomized trial (ASCENT; NCT02574455) conducted in 529 pa- The FDA approved isatuximab-irfc in combination with carfilzomib and tients with unresectable locally advanced or mTNBC who had re- dexamethasone for the treatment of adult patients with relapsed or re- lapsed after at least two prior chemotherapies, one of which could fractory multiple myeloma who have received 1-3 prior lines of therapy. be in the neoadjuvant or adjuvant setting, if progression occurred The efficacy and safety of isatuximab-irfc in combination with carfil- within 12 months. Patients were randomized (1:1) to receive saci- zomib and dexamethasone was evaluated in IKEMA (NCT03275285), tuzumab govitecan, 10 mg/kg as an intravenous infusion, on days 1 a multicenter, multinational, randomized, open-label, two-arm, Phase and 8 of a 21-day (n=267) cycle or physician’s choice of single-agent III trial in patients with relapsed and/or refractory multiple myeloma chemotherapy (n=262). who had received 1-3 prior lines of therapy. The trial randomized 302 The primary efficacy endpoint was progression-free survival (PFS) patients (3:2) to receive isatuximab-irfc with carfilzomib and dexa- in patients without brain metastases at baseline as measured by a methasone (Isa-Kd) or carfilzomib and dexamethasone (Kd). blinded, independent, centralized review assessed using RECIST 1.1 The main efficacy outcome measure was progression-free survival criteria. Additional efficacy endpoints included PFS for the full popu- (PFS), assessed by an independent response committee based on central lation (with and without brain metastases) and overall survival (OS). laboratory data for M-protein and central radiologic imaging review us- Among all randomized patients (with and without brain metasta- ing International Myeloma Working Group criteria. Median PFS was ses), median PFS for patients receiving sacituzumab govitecan was 4.8 not reached in the Isa-Kd arm and was 20.27 months (95% CI: 15.77- months (95% CI: 4.1, 5.8) compared with 1.7 months (95% CI: 1.5, NR) in the Kd arm (HR 0.548; 95% CI: 0.366-0.822; p=0.0032), repre- 2.5) in those receiving chemotherapy (HR 0.43; 95% CI: 0.35, 0.54; senting a 45 percent reduction in the risk of disease progression or death p<0.0001). Median OS was 11.8 months (95% CI: 10.5, 13.8) and 6.9 in patients treated with Isa-Kd compared to those treated with Kd. months (95% CI: 5.9, 7.6), respectively (HR 0.51; 95% CI: 0.41, 0.62; The most common adverse reactions (≥20%) in patients receiving p<0.0001). isatuximab with carfilzomib and dexamethasone were upper respiratory Most common adverse reactions (incidence >25%) in patients re- tract infection, infusion-related reactions, fatigue, hypertension, diar- ceiving sacituzumab govitecan were nausea, neutropenia, diarrhea, rhea, pneumonia, dyspnea, insomnia, bronchitis, cough, and back pain. fatigue, alopecia, anemia, vomiting, constipation, rash, decreased ap- The most common hematology laboratory abnormalities (≥80%) were petite, and abdominal pain. decreased hemoglobin, decreased lymphocytes, and decreased platelets. The recommended sacituzumab govitecan dose is 10 mg/kg once The recommended isatuximab-irfc dose with carfilzomib and weekly on days 1 and 8 of 21-day treatment cycles until disease pro- dexamethasone is 10 mg/kg as an intravenous infusion every week gression or unacceptable toxicity. for 4 weeks followed by every 2 weeks until disease progression or un- acceptable toxicity. Breakthrough Therapy Designation to Futibatinib for Advanced Cholangiocarcinoma A New Dosing Regimen for Cetuximab The FDA granted Breakthrough Therapy Designation for futi- The FDA approved a new dosage regimen of 500 mg/m2 as a batinib (TAS-120), a covalently binding FGFR inhibitor, for the 120- minute intravenous infusion every 2 weeks (Q2W) for cetuximab treatment of patients with previously treated locally advanced or for patients with KRAS wild-type, EGFR-expressing colorectal cancer metastatic cholangiocarcinoma harboring FGFR2 gene rearrange- 36 Oncology Times May 5, 2021 ments, including gene fusions. Futibatinib is an investigational cancer is the integration of leading-edge technologies into gastroen- therapy and has not been approved by any regulatory authority for terology practices to increase detection rates,” said James Weber, MD, use in patients. a gastroenterologist and Chief Executive Officer of the GI Alliance. The designation is based on efficacy and safety results from the “Detection of adenomas during colonoscopy is an important qual- Phase II FOENIX-CCA2 study. In May 2018, the FDA Office of ity metric. The addition of AI can increase the quality of colonosco- Orphan Drug Development granted futibatinib orphan drug status pies, potentially improving diagnosis and outcomes for colon cancer for the treatment of cholangiocarcinoma. Futibatinib is an investiga- patients.” tional, oral, potent, selective, and irreversible small molecule inhibitor “Colonoscopies allow highly skilled gastroenterologists to identify of FGFR1, 2, 3 and 4 being studied as a potential treatment for pa- polyps and lesions that might develop into cancer. With GI Genius, tients with advanced solid tumors with FGFR1-4 genetic aberrations, we can tap into the potential of artificial intelligence approaches to including cholangiocarcinoma, who were previously treated with che- increase detection rates. This important new development helps us motherapy or other therapies. Futibatinib selectively and irreversibly in our mission to detect colon cancer early and to improve patient binds to the ATP binding pocket of FGFR1-4, resulting in the inhi- outcomes,” said Michael Sapienza, Chief Executive Officer of the bition of FGFR-mediated signal transduction pathways, reduced tu- Colorectal Cancer Alliance. mor cell proliferation, and increased tumor cell death in tumors with The detection system uses advanced AI to highlight the presence FGFR1-4 genetic aberrations. of precancerous lesions with a visual marker in real-time—serving as an ever vigilant second observer. It processes images using advanced Fast Track Designation for Annamycin in the algorithms that can identify and mark abnormalities consistent with Treatment of Sarcoma Lung Metastases polyps, including small flat polyps that might otherwise go undetected The FDA approved a Fast Track Designation request for the drug, by the human eye. Studies have shown that having a second observer annamycin, for the treatment of soft tissue sarcoma (STS) lung can increase polyp detection rates and every 1 percent increase in ad- metastases.
Load more

Recommended publications
  • Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients
    antibodies Review Pharmacologic Considerations in the Disposition of Antibodies and Antibody-Drug Conjugates in Preclinical Models and in Patients Andrew T. Lucas 1,2,3,*, Ryan Robinson 3, Allison N. Schorzman 2, Joseph A. Piscitelli 1, Juan F. Razo 1 and William C. Zamboni 1,2,3 1 University of North Carolina (UNC), Eshelman School of Pharmacy, Chapel Hill, NC 27599, USA; [email protected] (J.A.P.); [email protected] (J.F.R.); [email protected] (W.C.Z.) 2 Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; [email protected] 3 Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; [email protected] * Correspondence: [email protected]; Tel.: +1-919-966-5242; Fax: +1-919-966-5863 Received: 30 November 2018; Accepted: 22 December 2018; Published: 1 January 2019 Abstract: The rapid advancement in the development of therapeutic proteins, including monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs), has created a novel mechanism to selectively deliver highly potent cytotoxic agents in the treatment of cancer. These agents provide numerous benefits compared to traditional small molecule drugs, though their clinical use still requires optimization. The pharmacology of mAbs/ADCs is complex and because ADCs are comprised of multiple components, individual agent characteristics and patient variables can affect their disposition. To further improve the clinical use and rational development of these agents, it is imperative to comprehend the complex mechanisms employed by antibody-based agents in traversing numerous biological barriers and how agent/patient factors affect tumor delivery, toxicities, efficacy, and ultimately, biodistribution.
    [Show full text]
  • Antibody–Drug Conjugates
    Published OnlineFirst April 12, 2019; DOI: 10.1158/1078-0432.CCR-19-0272 Review Clinical Cancer Research Antibody–Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index Steven Coats1, Marna Williams1, Benjamin Kebble1, Rakesh Dixit1, Leo Tseng1, Nai-Shun Yao1, David A. Tice1, and Jean-Charles Soria1,2 Abstract Since the first approval of gemtuzumab ozogamicin nism of activity of the cytotoxic warhead. However, the (Mylotarg; Pfizer; CD33 targeted), two additional antibody– enthusiasm to develop ADCs has not been dampened; drug conjugates (ADC), brentuximab vedotin (Adcetris; Seat- approximately 80 ADCs are in clinical development in tle Genetics, Inc.; CD30 targeted) and inotuzumab ozogami- nearly 600 clinical trials, and 2 to 3 novel ADCs are likely cin (Besponsa; Pfizer; CD22 targeted), have been approved for to be approved within the next few years. While the hematologic cancers and 1 ADC, trastuzumab emtansine promise of a more targeted chemotherapy with less tox- (Kadcyla; Genentech; HER2 targeted), has been approved to icity has not yet been realized with ADCs, improvements treat breast cancer. Despite a clear clinical benefit being dem- in technology combined with a wealth of clinical data are onstrated for all 4 approved ADCs, the toxicity profiles are helping to shape the future development of ADCs. In this comparable with those of standard-of-care chemotherapeu- review, we discuss the clinical and translational strategies tics, with dose-limiting toxicities associated with the mecha- associated with improving the therapeutic index for ADCs. Introduction in antibody, linker, and warhead technologies in significant depth (2, 3, 8, 9). Antibody–drug conjugates (ADC) were initially designed to leverage the exquisite specificity of antibodies to deliver targeted potent chemotherapeutic agents with the intention of improving Overview of ADCs in Clinical Development the therapeutic index (the ratio between the toxic dose and the Four ADCs have been approved over the last 20 years (Fig.
    [Show full text]
  • Antibody–Drug Conjugates: the Last Decade
    pharmaceuticals Review Antibody–Drug Conjugates: The Last Decade Nicolas Joubert 1,* , Alain Beck 2 , Charles Dumontet 3,4 and Caroline Denevault-Sabourin 1 1 GICC EA7501, Equipe IMT, Université de Tours, UFR des Sciences Pharmaceutiques, 31 Avenue Monge, 37200 Tours, France; [email protected] 2 Institut de Recherche Pierre Fabre, Centre d’Immunologie Pierre Fabre, 5 Avenue Napoléon III, 74160 Saint Julien en Genevois, France; [email protected] 3 Cancer Research Center of Lyon (CRCL), INSERM, 1052/CNRS 5286/UCBL, 69000 Lyon, France; [email protected] 4 Hospices Civils de Lyon, 69000 Lyon, France * Correspondence: [email protected] Received: 17 August 2020; Accepted: 10 September 2020; Published: 14 September 2020 Abstract: An armed antibody (antibody–drug conjugate or ADC) is a vectorized chemotherapy, which results from the grafting of a cytotoxic agent onto a monoclonal antibody via a judiciously constructed spacer arm. ADCs have made considerable progress in 10 years. While in 2009 only gemtuzumab ozogamicin (Mylotarg®) was used clinically, in 2020, 9 Food and Drug Administration (FDA)-approved ADCs are available, and more than 80 others are in active clinical studies. This review will focus on FDA-approved and late-stage ADCs, their limitations including their toxicity and associated resistance mechanisms, as well as new emerging strategies to address these issues and attempt to widen their therapeutic window. Finally, we will discuss their combination with conventional chemotherapy or checkpoint inhibitors, and their design for applications beyond oncology, to make ADCs the magic bullet that Paul Ehrlich dreamed of. Keywords: antibody–drug conjugate; ADC; bioconjugation; linker; payload; cancer; resistance; combination therapies 1.
    [Show full text]
  • 1 Oncologic Drugs Advisory Committee (ODAC)
    Oncologic Drugs Advisory Committee (ODAC) Meeting April, 27, 2021 BLA# 761034/Supplement 18 Drug name: TECENTRIQ® (atezolizumab) Applicant: Genentech, Inc. Combined FDA and Applicant ODAC Briefing Document Advisory Committee Briefing Materials: Available For Public Release 1 DISCLAIMER STATEMENT The attached package contains background information prepared by the Applicant and the Food and Drug Administration (FDA) for the panel members of the advisory committee. The package contains assessments and/or conclusions and recommendations written by individual FDA reviewers. Such conclusions and recommendations do not necessarily represent the final position of the individual reviewers, nor do they necessarily represent the final position of the Review Division or Office. We have brought the drug TECENTRIQ® (also known as atezolizumab) to this Advisory Committee in order to gain the Committee’s insights and opinions, and the background package may not include all issues relevant to the final regulatory recommendation and instead is intended to focus on issues identified by the Agency for discussion by the advisory committee. The FDA will not issue a final determination on the issues at hand until input from the advisory committee process has been considered and all reviews have been finalized. The final determination may be affected by issues not discussed at the advisory committee meeting. 2 Table of Contents Table of Tables .........................................................................................................................
    [Show full text]
  • New Drug Updates Brendan Mangan, Pharmd Clinical Pharmacy Specialist Hospital of the University of Pennsylvania
    11/9/2020 Disclosures • There are no relevant financial interests to disclose for myself or my spouse/partner from within the last 12 months New Drug Updates Brendan Mangan, PharmD Clinical Pharmacy Specialist Hospital of the University of Pennsylvania 1 2 Objectives New Drugs Explain the pharmacology of each new medication Malignant Hematology Medical Oncology Define indications, adverse effects and pertinent drug interactions Outline supportive care measures and clinical pearls Selinexor Tazemotostat Isatuximab-irfc Avapritinib Discuss the results of clinical trials and place in therapy Belantamab mafodotin-blmf Pexidartinib Fedratinib Entrectinib Polatuzumab vedotin-piiq Tafasitamab-cxix Zanubrutinib 3 4 Selinexor (XPOVIO®) Approval: July 3, 2019 Novel agent Exportin 1 inhibitor ▫ Reversibly inhibits nuclear export of tumor suppressor proteins, growth regulators, and mRNAs of oncogenic proteins XPOVI™ [Prescribing Information] Newton, MA. Karyopharm Therapeutics. 2019. Picture: xpovio.com 5 6 1 11/9/2020 Selinexor Selinexor Indication Adverse Effects Clinical Pearls • In combination with dexamethasone for relapse refractory multiple myeloma after failing 4 prior therapies Thrombocytopenia (74%) GCSF and prophylactic antimicrobials Recommended Neutropenia (34%) Prophylactic anti-emetics First Reduction Second Reduction Third Reduction Starting Dosage Nausea (72%)/Vomiting (41%) IV fluids and electrolyte repletion may be Diarrhea (44%) warranted monitor closely 80 mg Discontinue Days 1 and 3 of each Anorexia (53%)/Weight loss (47%) Correct sodium levels for concurrent 100 mg once weekly 80 mg once weekly 60 mg once weekly week (160 mg weekly Hyponatremia (39%) hyperglycemia (>150 mg/dL) total) Infections (52%) TPO agonist may be warranted for Neurological toxicity (30%) thrombocytopenia GCSF = Granulocyte colony-stimulating factor XPOVI™ [Prescribing Information] Newton, MA.
    [Show full text]
  • Immunotherapies Shape the Treatment Landscape for Hematologic Malignancies Jane De Lartigue, Phd
    Feature Immunotherapies shape the treatment landscape for hematologic malignancies Jane de Lartigue, PhD he treatment landscape for hematologic of TIL therapy has been predominantly limited to malignancies is evolving faster than ever melanoma.1,3,4 before, with a range of available therapeutic Most recently, there has been a substantial buzz Toptions that is now almost as diverse as this group around the idea of genetically engineering T cells of tumors. Immunotherapy in particular is front and before they are reintroduced into the patient, to center in the battle to control these diseases. Here, increase their anti-tumor efficacy and minimize we describe the latest promising developments. damage to healthy tissue. This is achieved either by manipulating the antigen binding portion of the Exploiting T cells T-cell receptor to alter its specificity (TCR T cells) The treatment landscape for hematologic malig- or by generating artificial fusion receptors known as nancies is diverse, but one particular type of therapy chimeric antigen receptors (CAR T cells; Figure 1). has led the charge in improving patient outcomes. The former is limited by the need for the TCR to be Several features of hematologic malignancies may genetically matched to the patient’s immune type, make them particularly amenable to immunother- whereas the latter is more flexible in this regard and apy, including the fact that they are derived from has proved most successful. corrupt immune cells and come into constant con- CARs are formed by fusing part of the single- tact with other immune cells within the hemato- chain variable fragment of a monoclonal antibody poietic environment in which they reside.
    [Show full text]
  • Antibodies to Watch in 2021 Hélène Kaplona and Janice M
    MABS 2021, VOL. 13, NO. 1, e1860476 (34 pages) https://doi.org/10.1080/19420862.2020.1860476 PERSPECTIVE Antibodies to watch in 2021 Hélène Kaplona and Janice M. Reichert b aInstitut De Recherches Internationales Servier, Translational Medicine Department, Suresnes, France; bThe Antibody Society, Inc., Framingham, MA, USA ABSTRACT ARTICLE HISTORY In this 12th annual installment of the Antibodies to Watch article series, we discuss key events in antibody Received 1 December 2020 therapeutics development that occurred in 2020 and forecast events that might occur in 2021. The Accepted 1 December 2020 coronavirus disease 2019 (COVID-19) pandemic posed an array of challenges and opportunities to the KEYWORDS healthcare system in 2020, and it will continue to do so in 2021. Remarkably, by late November 2020, two Antibody therapeutics; anti-SARS-CoV antibody products, bamlanivimab and the casirivimab and imdevimab cocktail, were cancer; COVID-19; Food and authorized for emergency use by the US Food and Drug Administration (FDA) and the repurposed Drug Administration; antibodies levilimab and itolizumab had been registered for emergency use as treatments for COVID-19 European Medicines Agency; in Russia and India, respectively. Despite the pandemic, 10 antibody therapeutics had been granted the immune-mediated disorders; first approval in the US or EU in 2020, as of November, and 2 more (tanezumab and margetuximab) may Sars-CoV-2 be granted approvals in December 2020.* In addition, prolgolimab and olokizumab had been granted first approvals in Russia and cetuximab saratolacan sodium was first approved in Japan. The number of approvals in 2021 may set a record, as marketing applications for 16 investigational antibody therapeutics are already undergoing regulatory review by either the FDA or the European Medicines Agency.
    [Show full text]
  • Sarclisa, INN-Isatuximab
    ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS 1 This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions. 1. NAME OF THE MEDICINAL PRODUCT SARCLISA 20mg/mL concentrate for solution for infusion. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION One ml of concentrate for solution for infusion contains 20 mg of isatuximab. Each vial contains 100 mg of isatuximab in 5 mL of concentrate (100 mg/5mL). Each vial contains 500 mg of isatuximab in 25 mL of concentrate (500 mg/25mL). Isatuximab is an immunoglobulin G1 (IgG1) monoclonal antibody (mAb) produced from a mammalian cell line (Chinese Hamster Ovary, CHO). For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Concentrate for solution for infusion. Colourless to slightly yellow solution, essentially free of visible particulates. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications SARCLISA is indicated: - in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on the last therapy. - in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.1). 4.2 Posology and method
    [Show full text]
  • Provider Newsletter April 2021
    Medicaid Managed Care Dual Advantage Provider Newsletter April 2021 https://providers.healthybluela.com Provider Services: Medicaid — 1-844-521-6942, Medicare — reference the back of your patient’s member ID card Table of Contents COVID-19 information from Page 2 Healthy Blue Medicaid: MCG Care Guidelines Page 2 24th edition customization Dual Advantage: Medical drug benefit Page 3 Clinical Criteria updates In-Office Assessment Page 4 program Oncology Dose Reduction Program beginning Page 6 July 1, 2021 Want to receive the Provider Newsletter via email? Click here to provide/update your email address. BLA-NL-0301-21 Healthy Blue is the trade name of Community Care Health Plan of Louisiana, Inc., an independent licensee of the Blue Cross and Blue Shield Association. COVID-19 information from Healthy Blue Healthy Blue is closely monitoring COVID-19 developments and how the novel coronavirus will impact our customers and provider partners. Our clinical team is actively monitoring external queries and reports from the Centers for Disease Control and Prevention (CDC) and the Louisiana Department of Health (LDH) to help us determine what action is necessary on our part. Healthy Blue will continue to follow LDH guidance policies. For additional information, reference the COVID-19 News and Updates section of our website. BLAPEC-1682-20/BLACARE-0163-20 Medicaid MCG Care Guidelines 24th edition customization Effective March 12, 2021, the following new customizations will be implemented: • Gastrointestinal Bleeding, Upper (W0170, previously ORG M-180) — Customized the Clinical Indications for admission to inpatient care by revising the hemoglobin, systolic blood pressure, pulse, melena, orthostatic hypotension and BUN criteria.
    [Show full text]
  • Northwest Medical Benefit Formulary (List of Covered Drugs) Please Read
    Northwest Medical Benefit Formulary (List of Covered Drugs) Please Read: This document contains information about the drugs we cover when they are administered to you in a Participating Medical Office. What is the Kaiser Permanente Northwest Medical Benefit Formulary? A formulary is a list of covered drugs chosen by a group of Kaiser Permanente physicians and pharmacists known as the Formulary and Therapeutics Committee. This committee meets regularly to evaluate and select the safest, most effective medications for our members. Kaiser Permanente Formulary The formulary list that begins on the next page provides information about some of the drugs covered by our plan when they are administered to you in a Participating Medical Office. Depending on your medical benefits, you may pay a cost share for the drug itself. The first column of the chart lists the drug’s generic name. The second column lists the brand name. Most administered medications and vaccines are only available as brand name drugs. Contraceptive Drugs and Devices Your provider may prescribe as medically necessary any FDA-approved contraceptive drug or device, including those on this formulary, which you will receive at no cost share. Last Updated 09/01/2021 Generic Name Brand Name Clinic Administered Medications (ADMD) ABATACEPT ORENCIA ABOBOTULINUM TOXIN A DYSPORT ADALIMUMAB HUMIRA ADO-TRASTUZUMAB EMTANSINE KADCYLA AFAMELANOTIDE ACETATE SCENESSE AFLIBERCEPT EYLEA AGALSIDASE BETA FABRAZYME ALDESLEUKIN PROLEUKIN ALEMTUZUMAB LEMTRADA ALGLUCOSIDASE ALFA LUMIZYME ARALAST, GLASSIA,
    [Show full text]
  • Antibodies for the Treatment of Brain Metastases, a Dream Or a Reality?
    pharmaceutics Review Antibodies for the Treatment of Brain Metastases, a Dream or a Reality? Marco Cavaco, Diana Gaspar, Miguel ARB Castanho * and Vera Neves * Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Av. Prof. Egas Moniz, 1649-028 Lisboa, Portugal * Correspondence: [email protected] (M.A.R.B.C.); [email protected] (V.N.) Received: 19 November 2019; Accepted: 28 December 2019; Published: 13 January 2020 Abstract: The incidence of brain metastases (BM) in cancer patients is increasing. After diagnosis, overall survival (OS) is poor, elicited by the lack of an effective treatment. Monoclonal antibody (mAb)-based therapy has achieved remarkable success in treating both hematologic and non-central-nervous system (CNS) tumors due to their inherent targeting specificity. However, the use of mAbs in the treatment of CNS tumors is restricted by the blood–brain barrier (BBB) that hinders the delivery of either small-molecules drugs (sMDs) or therapeutic proteins (TPs). To overcome this limitation, active research is focused on the development of strategies to deliver TPs and increase their concentration in the brain. Yet, their molecular weight and hydrophilic nature turn this task into a challenge. The use of BBB peptide shuttles is an elegant strategy. They explore either receptor-mediated transcytosis (RMT) or adsorptive-mediated transcytosis (AMT) to cross the BBB. The latter is preferable since it avoids enzymatic degradation, receptor saturation, and competition with natural receptor substrates, which reduces adverse events. Therefore, the combination of mAbs properties (e.g., selectivity and long half-life) with BBB peptide shuttles (e.g., BBB translocation and delivery into the brain) turns the therapeutic conjugate in a valid approach to safely overcome the BBB and efficiently eliminate metastatic brain cells.
    [Show full text]
  • Sanofi Genzyme Booklet
    Shu, Pompe Disease, Japan PATIENTS AND SCIENCE A LEADER IN SPECIALTY CARE Sanofi Genzyme is the specialty care global business unit of Sanofi, focused on ARE AT THE CENTER OF rare diseases, rare blood disorders, multiple sclerosis, oncology and immunology. We help people with debilitating and complex conditions that are often difficult EVERYTHING WE DO to diagnose and treat. We are dedicated to discovering and advancing new therapies, providing hope to patients and their families around the world. Leading with science and keeping Our ambition is to be the industry leader in specialty care. We currently provide patients at the center of our work more than 25 treatments to patients globally, with many potential new therapies defines and unites our efforts across rare in development. diseases, rare blood disorders, multiple sclerosis, oncology, and OUR APPROACH immunology. Our approach is shaped by a long history of developing highly specialized treatments and forging close relationships with physician and patient communities. Across each of the therapeutic areas where we focus, we work to identify and address unmet medical needs where patients do not have adequate treatment options. Our commitment to scientific discovery and innovation is foundational to our ability to serve our existing patient populations and offer hope to underserved patient populations in the future. This potential to improve patients’ lives inspires the 4800+ Sanofi Genzyme employees who work at the forefront of health care and biotechnology, along with thousands of Sanofi colleagues around the world. ABOUT SANOFI Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients’ needs.
    [Show full text]